NYSE:CVS

CVS Health Corp (CVS)

95.70
-0.52 (0.54%)
as of Aug 7, 2026, 8:00:00 pm Market Open.
410 watching
0
Investor Insights
star iconAug 8, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

CVS Health Corp is experiencing a notable turnaround, primarily driven by improvements in its managed care business and health services segment. Experts highlighted that the company recently reported strong earnings and revenue figures, raising its full-year guidance while its shares surged towards a three-year high. However, some analysts caution that while the stock appears cheap, it comes with inherent risks, particularly from performance in the retail pharmacy space, which has been struggling. Despite the current challenges, CVS has shown significant growth in pharmacy sales and overall revenues, aided by the exit of competitors like Rite Aid from the market. The CEO's leadership is receiving praise for revitalizing the company's operations and future prospects seem promising.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
UNH
PARTIAL SELL
A strategic review

It's been miserable and was exiting some of his position today. Maybe they will sell some of their businesses. Operating insurance and providing benefits has raised their costs and growth a lot. Regulations have also hurt. He doesn't see growth.

DON'T BUY

All healthcare companies starting in pharmacies have been vertically segments like insurance, but they've had a tough time, because pharmacies are low-margin and getting tougher. Also, governments are getting more involved in drug pricing. Thirdly, post Covid medical procedures remain high which also squeezes margins. He exited CVS 6-8 months ago.

DON'T BUY

Likes the pharmacy benefits division, but retail is soft and affecting overall earnings and revenues. Consumer is moving more toward online and e-commerce.

HOLD

Was originally a pharmacy then expanded into insurance and healthcare centres. Long run, it makes sense, but it had faced bumps. Their model will take a lot longer to play out, but they are the best at it. They are more than just a drug store. At current levels, you're fine to hold this.

DON'T BUY

Has sold shares in company. Unsure on why company has not been able to perform. Better options for investors out there. 

WATCH

They reported a solid quarter, but cut their full-year forecast for a third time. Total revenues were up YOY and their pharmacy business is doing well. They could turn things around.

DON'T BUY

The type of company he doesn't like to invest in. Swimming in debt, earnings not growing. What's the catalyst to take it higher? A complete mess. Huge competition. Healthcare space is so tough. There could be value here, but he wouldn't recommend it to anyone.

PAST TOP PICK
(A Top Pick Jun 28/23, Down 17%)

Market getting tired of missed earnings estimates. Company having trouble keeping sales up across business lines. However, retail presence and business overall still presenting value. Is one of the strong remaining brands left in the retail health companies. If company does not do any more M&A, and keeps balance sheet strong - should be ok. Expecting higher earnings going forward. Will continue to hold.

WATCH
Value stock or trap?

Reported earnings, stock came down. Will remain in penalty box for a couple of quarters. In a good sector, but continues to make missteps. Value trap right now. Over time should trend back up to $70, but you might be waiting a while.

Gets lumped in with WBA, but they're different businesses. Not keen on either right now, but he'd have a slight preference for CVS, as he knows it better.

BUY
Dipped on its benefits business.

Stable, much more broadly diversified than WBA. Way ahead of the curve on getting into homecare. Becoming a one-stop, end-to-end healthcare business. Generating free, excess cashflow that they're using for acquisitions without having to issue more shares. Dividend is more than secure, seeing share buybacks again.

DON'T BUY

Is concerned, because it's faster for Amazon to deliver the same products that a CVS store can sell him.

DON'T BUY

Stock price has been run over, but not a quality name. Will probably be a market share donor to a high-quality name like UNH, which he owns.

SELL

Reported dreadful results the other week, he sold. Painful, but enough was enough. Promise of vertical integration making it a juggernaut just didn't happen. 

Have to get used to being wrong as an investor some of the time. It's what you do when you're wrong that's a big factor in your results.

DON'T BUY

It is getting squeezed even by grocery stores operating their own pharmacies. Their acquisitions don't work out and it would be better to pick a different pharmaceutical company.

BUY

Painful, he owns and is down, but believes in long-term value of the enterprise. CEO's done a reasonably good job. Margins have fallen back as people use the healthcare system more and costs escalate. Overpaid for recent acquisition.

Really great enterprise, reasonably low valuation, nice dividend. With a time horizon of 2-5 years, stock could potentially double. Doesn't deserve the hammering it's had from comparisons to Covid times.

Showing 31 to 45 of 465 entries